Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis

BACKGROUND: This study evaluated the hemoglobin dose response, other efficacy measures and safety of daprodustat, an orally administered, hypoxia-inducible factor prolyl hydroxylase inhibitor in development for anemia of chronic kidney disease. METHODS: Participants (n = 216) with baseline hemoglobi...

Descripción completa

Detalles Bibliográficos
Autores principales: Meadowcroft, Amy M, Cizman, Borut, Holdstock, Louis, Biswas, Nandita, Johnson, Brendan M, Jones, Delyth, Nossuli, A Kaldun, Lepore, John J, Aarup, Michael, Cobitz, Alexander R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Anemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366140/
https://www.ncbi.nlm.nih.gov/pubmed/30746141
http://dx.doi.org/10.1093/ckj/sfy014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366140/
https://www.ncbi.nlm.nih.gov/pubmed/30746141
http://dx.doi.org/10.1093/ckj/sfy014

Ejemplares similares